The Medical Director will report to the VP of Clinical Development and serve as the primary medical lead for Karyopharm clinical trials with cross-functional study teams on clinical trial strategy, design, execution and medical monitoring. . This individual will have the opportunity to work on more than one trials in Phases 1 through 3 at a time depending on the stage and scale of the trials. The successful candidate will thrive in an innovative and fast-paced culture and enjoy bringing novel technology forward in addition to be a passionate contributor and a highly-effective internal and external team player.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company, based in Newton, MA, USA, focused on the discovery, development and commercialization of novel, first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a central mechanism of oncogenesis via the inhibition of exportins specifically XPO1. Selinexor, Karyopharm’s lead candidate, has been administered to patients with hematologic malignancies or solid tumors in clinical trials worldwide. Karyopharm is currently preparing for its first potential U.S. commercial launch in 2019.